Browse CYP2A7

Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.
Domain PF00067 Cytochrome P450
Function

Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.

> Gene Ontology
 
Biological Process GO:0001676 long-chain fatty acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006690 icosanoid metabolic process
GO:0019369 arachidonic acid metabolic process
GO:0019373 epoxygenase P450 pathway
GO:0033559 unsaturated fatty acid metabolic process
Molecular Function GO:0004497 monooxygenase activity
GO:0005506 iron ion binding
GO:0008391 arachidonic acid monooxygenase activity
GO:0008392 arachidonic acid epoxygenase activity
GO:0008395 steroid hydroxylase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0016712 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
GO:0019825 oxygen binding
GO:0020037 heme binding
GO:0046906 tetrapyrrole binding
GO:0070330 aromatase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-211859: Biological oxidations
R-HSA-211999: CYP2E1 reactions
R-HSA-211897: Cytochrome P450 - arranged by substrate type
R-HSA-211935: Fatty acids
R-HSA-1430728: Metabolism
R-HSA-211945: Phase 1 - Functionalization of compounds
R-HSA-211981: Xenobiotics
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CYP2A7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CYP2A7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.54 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CYP2A7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1350.439
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0210.967
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2520.566
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2660.593
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6570.693
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2460.882
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1220.885
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.180.922
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6450.722
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0790.909
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5810.536
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1520.447
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CYP2A7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.45.51.90.66
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.46.80.61
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CYP2A7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CYP2A7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CYP2A7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CYP2A7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CYP2A7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CYP2A7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCYP2A7
Namecytochrome P450, family 2, subfamily A, polypeptide 7
Aliases cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 7; CPA7; CYPIIA7; P450-IIA4; cytochrom ......
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CYP2A7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.